Eisai starts phase 3 trials for second Alzheimer’s drug after first’s failure

112
Plasminogen Activator Inhibitor market,
Plasminogen Activator Inhibitor market,

Eisai Co Ltd on Friday said it has begun phase 3 clinical trials of Alzheimer’s treatment BAN2401, a day after the Japanese drugmaker and U.S. partner Biogen Inc scrapped trials for another Alzheimer’s drug, aducanumab.

http://feeds.reuters.com/~r/reuters/healthNews/~3/hD1_xogbjOo/eisai-starts-phase-3-trials-for-second-alzheimers-drug-after-firsts-failure-idUSKCN1R303T